Kuczynskni et al., Dissertationes Pharmaceuticae et Pharmacologicae, 20(2), 169-177, 1968.* |
Dinarello, C. A., “Interleukin-1”, Reviews of Infectious Diseases, vol. 6, No. 1, pp. 51-95, 1984. |
Maini, R. et al., “Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial”, The Lancet, vol. 354, pp. 1932-1939, 1999. |
Weinblatt, M. E. et al., “A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptors:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate”, The New England J. of Medicine, vol. 340, No. 4, pp. 253-259, 1999. |
Pelletier, J.P., et al., “coordinate Synthesis of Stromelysin, Interleukin-1, and Oncogene Proteins in Experimental Osteoarthritis”, Amer. J. of Pathology, vol. 142, No. 1, pp. 95-105, 1993. |
Farahat, M.N. et al., “Cytokine Expression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis”, Annals of the Rheumatic Diseases, vol. 52, pp. 870-875, 1993. |
Tiku, K. et al., “Articular Chondrocytes Secrete IL-1, Express Membrane IL-1, and Have IL-1 Inhibitory Activity”, Cellular Immunology, Vo.. 140, pp. 1-20, 1992. |
Web, G. R., et al., “Chondrocyte tumor necrosis factor receptors and focal loss of cartilage in osteoarthritis”, Osteoarthritis and Cartilage, vol. 5, pp. 427-437, 1997. |
Westacott, A. F., et al., “Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis”, Osteoarthritis and Cartilage, vol. 8, pp. 213-221, 2000. |
McDaniel, M.L., et al., “Cytokines and Nitric Oxide in Islet Inflammation and Diabetes”, Proc. Soc. Exp. Biol. Med, vol. 211, No. 1, pp. 24-32, 1996. |
Rankin, E.C.C., et al., “The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Necrosis Factor alpha Antibody (CDP571) in Rheumatoid Arthritis” British J. of Rheumatology, vol. 34, pp. 334-342, 1995. |
Stack, W.A., et al., “Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease”, The Lancet, vol. 249, No. 9051, pp. 521-524, 1997. |
Han, J., et al., “Regulation of MEF2 by p38 MAPK and Its Implication in Cardiomyocyte Biology”, Trends Cardiovasc Med., vol. 10, No. 1, pp. 19-22, 2000. |
Hunter, J.J., et al., “Signaling Pathways for Cardiac Hypertrophy and Failure”, The New England J. of Medicine, vol. 341, No. 17, pp. 1276-1283, 1999. |
Behr, T.M., et al., “Sustained Activation of Cardiac P38 Mitogen Activated Protein Kinase in the Development of Heart Failure: Premature Mortality is Abolished by Chronic P38 Inhibition in Rat Model of Cardiac Hypertrophy and Failure”, Basic Science, vol. 102, pp. 289, 2000. |
Shimamoto, A., et al., “Inhibition of P38 Mitogen-Activated Protein Kinase Suppresses Interleukin-1β-Expression and Prevents Progression of Cardiac Hypertrophy and Congestive Heart Failure in Rats”, Basic Science, vol. 102, pp. 289, 2000. |
Aukrust, P., et al., “Cytokine Network in Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy”, Am. J. Cardiol, vol. 83, No. 3, pp. 376-382, 1999. |
Singh, A., et al., “Inducible Nitric Oxide Synthase in Vascular Smooth muscle Cells From Prehypertensive Spontaneously Hypertensive Rats”, Am. J. Hypertens., vol. 9, No. 9, pp. 867-877, 1996. |
Dinarello, C.A., “Interleukin-1 and Interleukin-1 Receptor Antagonist”, Supplement to Nutrition, vol. 11, No. 5, pp. 492-494, 1995. |
Rrenzetti, L.M., “Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways”, Inflammation Research, 46 Suppl. vol. 2, pp. S143-S144, 1997. |
Elhage, R. et al., “Differential Effects of Interleukin-1 Receptor antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in apolipoprotein E-Deficient Mice”, Circulation, vol. 97, No. 3, pp. 242-244, 1998. |
Howell, G.L., “Cytokine networks in destructive periodontal disease”, Oral Diseases, vol. 1, pp. 266-270, 1995. |
Holden, R.J. et al., “The Role of tumor Necrosis Factor-α in the Pathogenesis of anorexia and Bulimia Nervosa, Cancer Cachexia and Obesity”, Medical Hypotheses, vol. 47, pp. 423-438, 1996. |
Beisel, W.R., “Herman Award Lecture, 1995: Infection-induced malnutrition-from cholera to cytokines”, Am. J. Clin. Nutr., vol. 62, pp. 813-819, 1995. |
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, vol. 6, pp. 807-823, 1999. |
Foster, M.L. et al., “Potential of p38 Inhibitors in the Treatment of Rheumatoid Arthritis”, Drug News Perspect, vol. 13, No. 8, pp. 488-497, 2000. |
Adams, J.L. et al., “Pyrimidinylimidazole Inhibitors of CSBP/P38 Kinase Demonstrating Decreased Inhibition of Hepatic Cytochrome P450 Enzymes”, Bioorganic & Medicinal chemistry Letters, vol. 8, pp. 3111-3116, 1998. |